Evergreen Talk Series: Position paper published in JAPI indicated that Linagliptin is simplifying T2DM management in a Wide Range of Patients

Presenting the Evergreen Talk Series featuring Dr. Brij Mohan Makkar, a Senior Diabetologist and Obesity Specialist from Delhi, Dr Sameer I. Dani, an Interventional Cardiologist from Ahmedabad, and Dr. Tukaram Jamale, a Nephrologist and Kidney Transplant Physician who serves as the Head of the Department at KEM Hospital Mumbai. They provide their insights on the use of Linagliptin, Dapagliflozin, and Metformin for diabetic patients.

Bringing viewpoints from the different specialities of Diabetology, Cardiology and Nephrology they share their views about the use of Linagliptin for T2DM management and its applicability as monotherapy.

Dr Brij Mohan Makkar: Gliptins, as a class, are considered the safest option among Oral Antidiabetic Drugs (OADs). Now, of the gliptins, Linagliptin has the best profile. It is the only gliptin supported by two Cardiovascular Outcome Trials. The CAROLINA trial involved individuals with a high risk of atherosclerotic cardiovascular disease and renal risk patients, and Carolina was against an active comparator. Both studies clearly demonstrated its safety in terms of cardiovascular risk. Additionally, there are added benefits in terms of reducing albuminuria in individuals with early kidney involvement. This profile is one of the best options among antidiabetic agents, given its virtually no risk of hypoglycemia, no weight gain, decent reduction in HbA1c, compatibility with other oral agents, and lack of interactions with statins and antihypertensives.